ECTRIMS 2015 Conference Coverage

ECTRIMS 2015 Teriflunomide Slows Brain Atrophy in Relapsing Multiple Sclerosis

Teriflunomide Slows Brain Atrophy in Relapsing Multiple Sclerosis

Significant differences vs. placebo were maintained over 24 months.

ECTRIMS 2015 Rapid Assessment Tool Useful for Multiple Sclerosis Evaluation

Rapid Assessment Tool Useful for Multiple Sclerosis Evaluation

The test can be completed in about one minute and is free to use for clinicians and researchers.

ECTRIMS 2015 Expression of DICAM on TH17 Lymphocytes Documented in Neuroinflammation

Expression of DICAM on TH17 Lymphocytes Documented in Neuroinflammation

DICAM was strongly linked with expression of ROR-γ, IL-23R, IL-17, IL-22, GM-CSF, and GZMB expression in human CD4+ lymphocytes.

ECTRIMS 2015 NEDA-4 More Accurate Measure of Activity in Relapsing Multiple Sclerosis

NEDA-4 More Accurate Measure of Activity in Relapsing Multiple Sclerosis

The additional measure of brain volume loss results in a more comprehensive evaluation of disease activity in RRMS.

ECTRIMS 2015 Comorbid MS, Major Depressive Disorder Linked to Brain Volume Loss

Comorbid MS, Major Depressive Disorder Linked to Brain Volume Loss

Changes to brain structure indicate possible underlying connection to idiopathic major depressive disorder.

ECTRIMS 2015 Online Cognitive Behavioral Therapy Reduces Fatigue in Multiple Sclerosis

Online Cognitive Behavioral Therapy Reduces Fatigue in Multiple Sclerosis

Participants also reported a reduction in anxiety and subjective cognitive impairment.

ECTRIMS 2015 Smoking Cessation Slows Brain Volume Loss in Multiple Sclerosis

Smoking Cessation Slows Brain Volume Loss in Multiple Sclerosis

Compared to those who continued smoking, those who stopped experienced a significant decline in the rate of brain volume loss.

ECTRIMS 2015 Grey, White Matter Ratio and Disability in Relapsing-Remitting Multiple Sclerosis

Grey, White Matter Ratio and Disability in Relapsing-Remitting Multiple Sclerosis

The ratio was also predictive of conversion to secondary-progressive MS.

ECTRIMS 2015 Neurofilament Light Chain Level Predicts Brain Volume Loss at First Sign of MS

Neurofilament Light Chain Level Predicts Brain Volume Loss at First Sign of MS

CSF NfL levels were predictive of brain volume loss at first sign of MS and follow-up.

ECTRIMS 2015 Spinal Cord Grey Matter Atrophy Has Greatest Clinical Impact in MS

Spinal Cord Grey Matter Atrophy Has Greatest Clinical Impact in MS

Spinal cord gray matter atrophy was found to be most relevant compared to other conventional MRI metrics.

ECTRIMS 2015 Cervical Cord Atrophy, Lesions Predict Disability in Multiple Sclerosis

Cervical Cord Atrophy, Lesions Predict Disability in Multiple Sclerosis

Compared to RRMS, progressive MS had greater cord atrophy and lesions.

ECTRIMS 2015 Similar Effects Seen for Fingolimod, Placebo in Primary Progressive Multiple Sclerosis

Similar Effects Seen for Fingolimod, Placebo in Primary Progressive Multiple Sclerosis

No significant treatment effect on disease progression or brain or cervical spinal atrophy was observed.

Upcoming Meetings

Sign Up for Free e-newsletters